ORGENESIS INC (ORGS) Fundamental Analysis & Valuation
NASDAQ:ORGS • US68619K2042
Current stock price
2.11 USD
-1.13 (-34.84%)
At close:
2.25 USD
+0.14 (+6.64%)
After Hours:
This ORGS fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. ORGS Profitability Analysis
1.1 Basic Checks
- ORGS had negative earnings in the past year.
- ORGS had a negative operating cash flow in the past year.
- In the past 5 years ORGS reported 4 times negative net income.
- In the past 5 years ORGS always reported negative operating cash flow.
1.2 Ratios
- ORGS has a Return On Assets of -124.09%. This is amonst the worse of the industry: ORGS underperforms 81.71% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -124.09% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-142.32%
ROA(5y)-90.32%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- ORGS does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. ORGS Health Analysis
2.1 Basic Checks
- ORGS does not have a ROIC to compare to the WACC, probably because it is not profitable.
- Compared to 1 year ago, ORGS has more shares outstanding
- ORGS has a worse debt/assets ratio than last year.
2.2 Solvency
- Based on the Altman-Z score of -12.18, we must say that ORGS is in the distress zone and has some risk of bankruptcy.
- Looking at the Altman-Z score, with a value of -12.18, ORGS is doing worse than 79.93% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -12.18 |
ROIC/WACCN/A
WACC7.32%
2.3 Liquidity
- A Current Ratio of 0.07 indicates that ORGS may have some problems paying its short term obligations.
- ORGS's Current ratio of 0.07 is on the low side compared to the rest of the industry. ORGS is outperformed by 98.76% of its industry peers.
- A Quick Ratio of 0.07 indicates that ORGS may have some problems paying its short term obligations.
- ORGS's Quick ratio of 0.07 is on the low side compared to the rest of the industry. ORGS is outperformed by 98.76% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.07 | ||
| Quick Ratio | 0.07 |
3. ORGS Growth Analysis
3.1 Past
- ORGS shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -125.83%.
- The Revenue for ORGS has decreased by -98.14% in the past year. This is quite bad
- The Revenue for ORGS have been decreasing by -50.95% on average. This is quite bad
EPS 1Y (TTM)-125.83%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-52.75%
Revenue 1Y (TTM)-98.14%
Revenue growth 3Y-58.93%
Revenue growth 5Y-50.95%
Sales Q2Q%-96.47%
3.2 Future
- No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y190.48%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year39.76%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
- No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. ORGS Valuation Analysis
4.1 Price/Earnings Ratio
- The Price/Earnings Ratio is negative for ORGS. In the last year negative earnings were reported.
- ORGS is valuated cheaply with a Price/Forward Earnings ratio of 3.39.
- 99.29% of the companies in the same industry are more expensive than ORGS, based on the Price/Forward Earnings ratio.
- The average S&P500 Price/Forward Earnings ratio is at 22.19. ORGS is valued rather cheaply when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 3.39 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- ORGS's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A
5. ORGS Dividend Analysis
5.1 Amount
- No dividends for ORGS!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
ORGS Fundamentals: All Metrics, Ratios and Statistics
2.11
-1.13 (-34.84%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-13 2024-08-13/bmo
Earnings (Next)11-11 2024-11-11/bmo
Inst Owners3.18%
Inst Owner Change0%
Ins Owners790.6%
Ins Owner Change0%
Market Cap10.06M
Revenue(TTM)662.00K
Net Income(TTM)-37.94M
Analysts82.86
Price Target6.12 (190.05%)
Short Float %0.14%
Short Ratio0.03
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-98.66%
Min Revenue beat(2)-98.85%
Max Revenue beat(2)-98.46%
Revenue beat(4)0
Avg Revenue beat(4)-98.92%
Min Revenue beat(4)-99.2%
Max Revenue beat(4)-98.46%
Revenue beat(8)2
Avg Revenue beat(8)-49.23%
Revenue beat(12)4
Avg Revenue beat(12)-34.26%
Revenue beat(16)6
Avg Revenue beat(16)-8.82%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 3.39 | ||
| P/S | 15.2 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)-1.17
EYN/A
EPS(NY)0.62
Fwd EY29.49%
FCF(TTM)-2.63
FCFYN/A
OCF(TTM)-2.52
OCFYN/A
SpS0.14
BVpS-3.25
TBVpS-5.33
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -124.09% | ||
| ROE | N/A | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-142.32%
ROA(5y)-90.32%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.02
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 34.15% | ||
| Cap/Sales | 75.68% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.07 | ||
| Quick Ratio | 0.07 | ||
| Altman-Z | -12.18 |
F-Score2
WACC7.32%
ROIC/WACCN/A
Cap/Depr(3y)394.92%
Cap/Depr(5y)321.88%
Cap/Sales(3y)150.7%
Cap/Sales(5y)156.63%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-125.83%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-52.75%
EPS Next Y190.48%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-98.14%
Revenue growth 3Y-58.93%
Revenue growth 5Y-50.95%
Sales Q2Q%-96.47%
Revenue Next Year39.76%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-231.92%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y59.18%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y39.92%
OCF growth 3YN/A
OCF growth 5YN/A
ORGENESIS INC / ORGS Fundamental Analysis FAQ
What is the ChartMill fundamental rating of ORGENESIS INC (ORGS) stock?
ChartMill assigns a fundamental rating of 1 / 10 to ORGS.
What is the valuation status of ORGENESIS INC (ORGS) stock?
ChartMill assigns a valuation rating of 4 / 10 to ORGENESIS INC (ORGS). This can be considered as Fairly Valued.
Can you provide the profitability details for ORGENESIS INC?
ORGENESIS INC (ORGS) has a profitability rating of 0 / 10.
What is the earnings growth outlook for ORGENESIS INC?
The Earnings per Share (EPS) of ORGENESIS INC (ORGS) is expected to grow by 190.48% in the next year.